Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Buzz Bomb Caffeine Company is a wholly owned subsidiary of Aspire Biopharma Holdings, Inc., specializing in high-performance caffeine supplements. The company's flagship product, BUZZ BOMB, is a proprietary sublingual caffeine powder delivered in single-serving stick packs designed for rapid absorption and immediate energy. Utilizing Aspire's innovative sublingual nano-technology, the product bypasses the digestive system to provide mental focus and sustained energy without the crash associated with traditional energy drinks. Buzz Bomb targets athletes, professionals, and fitness enthusiasts through direct-to-consumer and retail channels. The brand is a key component of Aspire's strategy to monetize its delivery platform while advancing clinical-stage pharmaceutical candidates.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Buzz Bomb Caffeine Company.